Entrada Therapeutics Inc. Common Stock (TRDA)
Stock · NASDAQ · Health Care
$4.37as of 10/16/2026
Price chart
Active signals
TRDA Signal Track Record
How signals performed across all stocks →What TRDA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -1.7% | 47% | September 3, 2026 |
| Bollinger Band BreakdownActive now | 22 | +4.3% | 59% | September 24, 2026 |
| Bollinger Band Breakout | 21 | -3.8% | 48% | August 12, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +9.7% | 79% | September 10, 2024 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since August 16, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TRDA
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neur…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 152
- Website
- www.entradatx.com/
Fundamentals
- 1-day range
- $4.43$4.96
- Market cap
- $266.70M
- P/E (trailing)
- —
- P/E (forward)
- -1.59
- EPS (trailing)
- $-3.97
- Dividend yield
- —
- Beta
- -0.22
- Avg. volume
- 358.5K
How Entrada Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Entrada Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
- ADAGAdagene Inc. American Depositary Shares$2.06▼ 14.17%Market cap $273.45MP/E —$1.3$4.85
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
| ADAG Adagene Inc. American Depositary Shares | $273.45M | — | $2.06 | ▼ 14.17% | $1.3$4.85 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- What's Going On With Entrada Therapeutics Stock Wednesday?benzinga · 10/14/2026
- Alpha Buying: Follow the Money From NVIDIA and MerckBenzinga · 9/24/2026
Insider Activity
Insider Actions →- MPM BIOVENTURES 2018, L.P. · September 9, 2026 · Sale28.8K @ $7.13
- MPM BioVentures 2014, L.P. · September 9, 2026 · Sale28.8K @ $7.13
- MPM BIOVENTURES 2018, L.P. · September 8, 2026 · Sale192.5K @ $7.41
- MPM BioVentures 2014, L.P. · September 8, 2026 · Sale192.5K @ $7.41
- MPM BioVentures 2014, L.P. · September 4, 2026 · Sale38.5K @ $7.11
- MPM BIOVENTURES 2018, L.P. · September 4, 2026 · Sale38.5K @ $7.11
- MPM BIOVENTURES 2018, L.P. · September 3, 2026 · Sale32.3K @ $7.17
- MPM BioVentures 2014, L.P. · September 3, 2026 · Sale32.3K @ $7.17
- Natarajan Sethuraman · September 2, 2026 · Tax Withholding2.1K @ $7.14
- Nathan J. Dowden · September 2, 2026 · Tax Withholding2.5K @ $7.14
- Kory James Wentworth · September 2, 2026 · Tax Withholding1.7K @ $7.14
- MPM BIOVENTURES 2018, L.P. · September 2, 2026 · Sale25.1K @ $7.19
- Dipal Doshi · September 2, 2026 · Tax Withholding8.7K @ $7.14
- MPM BioVentures 2014, L.P. · September 2, 2026 · Sale25.1K @ $7.19
- MPM BIOVENTURES 2018, L.P. · September 1, 2026 · Sale29.1K @ $7.06
Institutional Ownership
March 31, 2026
- Total shares held
- 25.08M
- Total value held
- $305.35M
- Institutional holders
- 114
- Unknown5.07M
- Unknown4.06M
- Unknown2.36M
- Unknown2.29M
- Unknown1.26M
- Unknown1.03M
- Unknown761.3K
- Unknown667.3K
- Unknown533.8K
- Unknown526.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TRDA sees institutional interest from NVIDIA and Merck
The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.
TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.